Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.
Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data
The new-look mitral valve is built using LifePolymer, a proprietary material that does not include any animal tissue. Both the frame and its leaflets are robotically generated to match each patient’s anatomy.
Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference
Cerebral embolic protection devices are proven to work. However, according to one cardiologist, they are still not consistently reducing stroke rates.
TTVR with Evoque system linked to positive real-world outcomes after 30 days
According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation.
A closer look at world’s first TAVR patient treated with new cerebral embolic protection device
The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Heart damage after TAVR: Follow-up imaging helps cardiologists anticipate problems

While cardiac damage reverses in many patients following treatment, it can actually continue to get worse in others.

TricValve Transcatheter Bicaval Valves System and HeartMate II LVAD

Cardiologists shed new light on treating severe tricuspid regurgitation in high-risk heart failure patients

The 80-year-old patient was experiencing severe TR and already had a HeartMate II LVAD.

Mitral valve repair: How a minimally invasive approach compares to conventional surgery

Researchers compared minithoracotomy, a minimally invasive procedure for treating degenerative mitral regurgitation, with conventional surgery, sharing their findings in JAMA. The research was previously presented as a late-breaking study at ACC.23.

Rethinking SAVR in the TAVR era: New Cleveland Clinic study explores data from nearly 3,500 patients

SAVR may be even safer for low-risk patients than previously believed, according to new research published in the Journal of Thoracic and Cardiovascular Surgery. What does this tell us about patient care going forward?

Cardiologists perform world’s first TAVR with new ultra-low profile valve

The 88-year-old patient was originally not seen as a viable candidate for TAVR or surgery.

The Wattson temporary pacing guidewire from Teleflex

FDA clears new guidewire used for valve delivery and ventricular pacing during TAVR, BAV procedures

The device, now on display at TVT 2023 in Phoenix, is scheduled to begin hitting the market in the months ahead.

Antithrombotic therapy after TAVR: Comparing warfarin to DAPT, SAPT

A new retrospective study from the Mayo Clinic focused on patients with no other need for anticoagulation.

Conformal Medical raises $35M to continue development, research of next-gen LAAO device

The new investments were announced as the company continues developing its CLAAS device for sealing the LAA during LAAO procedures.

Structural Heart Disease

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving

Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data

Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference

TTVR with Evoque system linked to positive real-world outcomes after 30 days

A closer look at world’s first TAVR patient treated with new cerebral embolic protection device